Kenneth C. Anderson
Co-Founder, Independent Director & Member of Scientific Advisory BoardDr. Kenneth C. Anderson, M.D., Ph.D., also known as Ken, was Member of the Scientific Advisory Board of Gilead Sciences, Inc. He is Member of Scientific Advisory Board at TOLREMO therapeutics AG since October 2025. He is Scientific Co-Founder of Predicta Biosciences, Inc. Dr. Anderson is Member of Scientific Advisory Board of Lytica Therapeutics, Inc. He was Director of the LeBow Institute for Myeloma Therapeutics. He is Co-Founder, Member of Scientific Advisory Board and Director at Dynamic Cell Therapies, Inc. He serves as a Member of Scientific Advisory Board at Starton Holdings, Inc. He is also a Doris Duke Distinguished Clinical Research Scientist and an American Cancer Society Clinical Research Professor. He is Co-Founder at NextRNA Therapeutics, Inc. and had served as its Director until June 2022. Dr. Anderson serves as Member of Scientific Advisory Board at Genenta Science s.r.l. He serves as the Member of Board of Advisors at All4Cure, Inc. He has been the Chief of Division of Hematologic Neoplasia at the Dana-Farber Cancer Institute since 2002. He serves as Director of Window Therapeutics, Inc. He serves as a Director of Starton Therapeutics, Inc. since September 2020. He serves as the Member of Scientific Advisory Board at Arch Oncology, Inc. Dr. Anderson serves as Member of Scientific Advisory Board at Precision BioSciences, Inc since January 16, 2019. Dr. Anderson has been Councilor at American Society of Hematology since January 2010. He is a Scientific Founder of Acetylon Pharmaceuticals, Inc. and OncoPep, Inc. He is the Founder of C4 Therapeutics, Inc and has been its Independent Director since December 2015. He has been an Attending Physician at the Bone Marrow Transplantation Service at Brigham and Women's Hospital since 1997. Dr. Anderson has been Vice Chairman of the Joint Program in Transfusion Medicine at Harvard Medical School since 2000. He serves as a Member of Managing Myeloma Advisory Board at MediCom Worldwide, Inc. He has been a Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute since 2000 and 2007, respectively. He serves as a Member of Scientific Advisory Board and Director at Acetylon Pharmaceuticals, Inc. He serves as a Member of Clinical Advisory Board at Nereus Pharmaceuticals, Inc. Dr. Anderson is a member of the Institute of Medicine of the National Academy of Sciences and served as President of the International Myeloma Society from 2011 until 2015. He serves as a Member of Scientific Advisory Board at Frequency Therapeutics, Inc. He serves as a Member of the Scientific Advisory Board at Signal Genetics, Inc. He served as a Director until November 2021 and serves as Member of Scientific Advisory Board at OncoPep, Inc. He has been Member of Clinical & Scientific Advisory Board at Telo Genomics Corp. (formerly known as 3D Signatures Inc.) since November 2016. He has been Member of Scientific Advisory Board at C4 Therapeutics, Inc. since November 17, 2016 and served as Member of Clinical Advisory Board until August 2021. He served as a Director at MANA Therapeutics, Inc. and served as its Member of Scientific Advisory Board until March 2023. He had been a Director of American Association of Cancer Research since April 2, 2012. He served as a Member of Clinical Advisory Board at Avalon Pharmaceuticals, Inc. since January 2007. He served as an Independent Director of Gentium S.p.a. since June 2005 and served as a Member of its Scientific Advisory Board. He served as a Member of Scientific Advisory Board at Infinity Pharmaceuticals, Inc. He served as a Member of Scientific Advisory Board at MannKind Corporation. He served as a Member of Scientific Advisory Board at Callisto Pharmaceuticals, Inc. (formerly, Webtronics Inc.) since August 5, 2003. He is a Member of 11 medical and scientific societies and serves on the editorial boards of 11 medical and scientific journals. He has been a Professor at the Dana-Farber Cancer Institute, Cancer Research and Clinical Care since 1980. Dr. Anderson has been a Professor of Medicine at Harvard Medical School since 2000 and a Kraft Family Professor of Medicine since 2002. He is a Leader in the discovery of pathways that regulate growth of multiple myeloma cells and in the testing in clinical trials of drugs that disrupt these pathways. He is a well-recognized Leader in multiple myeloma research and clinical drug development. He has over four decades of experience researching multiple myeloma in both laboratory and clinical settings. Dr. Anderson is the recipient of several awards including the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award; the American Association for Cancer Research Joseph H. Burchenal Award, the American Society of Hematology William Dameshek Prize and the American Society of Clinical Oncology David A. Karnofsky Award. He is a member of the Institute of Medicine of the National Academy of Sciences and has served as President of the International Myeloma Society and the American Society of Hematology. Dr. Anderson trained in internal medicine at John's Hopkins Hospital and completed hematology, medical oncology and tumor immunology training at DFCI. Dr. Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute. He received a B.A., summa cum laude from Boston University in 1973, an M.D. from Johns Hopkins University School of Medicine in 1977 and an M.A. from Harvard University in 2000.
Positions
- Company NameC4 Therapeutics, Inc.Stock CodeCCCCPositionCo-Founder, Independent Director & Member of Scientific Advisory BoardColleagues
- AJAndrew J. HirschCEO, President & Director
- RHRonald H. W. CooperIndependent Chairman
- KRKendra R. AdamsPrincipal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer
- LMLeonard M. J. ReynoChief Medical Officer
- NSNathanael S. GrayCo-Founder & Member of Scientific Advisory Board
- UKUtpal KoppikarIndependent Director
